Get the Stockscreener App
15.65
3.40%
-0.55
After Hours:
15.65
Spyre Therapeutics Inc stock is traded at $15.65, with a volume of 431.14K.
It is down -3.40% in the last 24 hours and down -1.51% over the past month.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
See More
Previous Close:
$16.20
Open:
$16.11
24h Volume:
431.14K
Relative Volume:
0.79
Market Cap:
$945.28M
Revenue:
$688.00K
Net Income/Loss:
$-170.19M
P/E Ratio:
-5.2872
EPS:
-2.96
Net Cash Flow:
$-154.68M
1W Performance:
-7.94%
1M Performance:
-1.51%
6M Performance:
-17.11%
1Y Performance:
-44.97%
1-Day Range:
$15.64
$16.11
1-Week Range:
$15.64
$17.13
52-Week Range:
$10.91
$40.26
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Name
Spyre Therapeutics Inc
Sector
Industry
Phone
(617) 651-5940
Address
221 CRESCENT STREET, WALTHAM
Compare SYRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
15.65 | 977.29M | 688.00K | -170.19M | -154.68M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-25 | Initiated | Leerink Partners | Outperform |
| Mar-18-25 | Initiated | Wolfe Research | Outperform |
| Sep-04-24 | Initiated | Wedbush | Outperform |
| Jul-16-24 | Initiated | Evercore ISI | Outperform |
| May-02-24 | Initiated | Robert W. Baird | Outperform |
| Mar-01-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Dec-11-23 | Initiated | Guggenheim | Buy |
| Dec-11-23 | Initiated | Jefferies | Buy |
| May-04-20 | Initiated | Piper Sandler | Overweight |
| Mar-21-19 | Initiated | JP Morgan | Overweight |
| Sep-04-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Apr-24-18 | Initiated | Evercore ISI | Outperform |
| Mar-14-18 | Reiterated | Needham | Buy |
View All
Spyre Therapeutics Inc Stock (SYRE) Latest News
Order flow analysis tools used on Spyre Therapeutics Inc.2025 AllTime Highs & Daily Volume Surge Trade Alerts - Newser
What’s next for Spyre Therapeutics Inc. stock price2025 Technical Overview & Safe Entry Trade Signal Reports - Newser
Does Spyre Therapeutics Inc. fit your quant trading model2025 Market Outlook & Momentum Based Trading Signals - Newser
Smart tools for monitoring Spyre Therapeutics Inc.’s price action2025 Trade Ideas & Consistent Growth Equity Picks - Newser
Combining price and volume data for Spyre Therapeutics Inc.Market Performance Recap & AI Driven Stock Price Forecasts - Newser
Wall Street Zen Upgrades Spyre Therapeutics (NASDAQ:SYRE) to "Hold" - MarketBeat
Exit strategy if you’re trapped in Spyre Therapeutics Inc.Dollar Strength & Consistent Return Investment Signals - Newser
Has Spyre Therapeutics Inc. formed a bullish divergenceWeekly Earnings Recap & Low Volatility Stock Suggestions - Newser
Technical signs of recovery in Spyre Therapeutics Inc.July 2025 Decliners & Weekly Market Pulse Updates - Newser
Spyre Therapeutics Inc. stock momentum explained2025 Historical Comparison & Growth Focused Investment Plans - Newser
Can swing trading help recover from Spyre Therapeutics Inc. losses2025 Analyst Calls & Consistent Profit Trade Alerts - Newser
Real time pattern detection on Spyre Therapeutics Inc. stockQuarterly Trade Review & Daily Risk Controlled Trade Plans - Newser
What high frequency data says about Spyre Therapeutics Inc.Market Trend Review & Risk Managed Investment Strategies - Newser
Should you hold or exit Spyre Therapeutics Inc. now2025 Market Overview & Safe Entry Point Identification - Newser
Is Spyre Therapeutics Inc. forming a bottoming basePortfolio Return Report & Free Expert Approved Momentum Trade Ideas - Newser
Adage Capital Partners GP L.L.C. Sells 226,800 Shares of Spyre Therapeutics, Inc. $SYRE - MarketBeat
Volume spikes in Spyre Therapeutics Inc. stock – what they mean2025 Price Momentum & AI Enhanced Trading Alerts - Newser
Visualizing Spyre Therapeutics Inc. stock with heatmapsJuly 2025 Drop Watch & Low Drawdown Investment Strategies - Newser
News impact scoring models applied to Spyre Therapeutics Inc.Weekly Market Report & Daily Technical Stock Forecast Reports - Newser
Published on: 2025-09-10 03:16:21 - Newser
Regression analysis insights on Spyre Therapeutics Inc. performancePortfolio Update Report & High Yield Stock Recommendations - Newser
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $53.40 Consensus Target Price from Analysts - MarketBeat
Will Spyre Therapeutics Inc. bounce back from current supportWall Street Watch & Verified Momentum Stock Watchlist - Newser
Price action breakdown for Spyre Therapeutics Inc.Weekly Profit Report & Technical Buy Zone Confirmations - Newser
Will Spyre Therapeutics Inc. rebound enough to break evenInsider Buying & Expert-Curated Trade Recommendations - Newser
Published on: 2025-09-10 00:27:42 - Newser
Long term hold vs stop loss in Spyre Therapeutics Inc.July 2025 Decliners & Low Drawdown Investment Strategies - Newser
Spyre Therapeutics Inc. stock trend forecastQuarterly Performance Summary & Community Trade Idea Sharing Platform - Newser
Published on: 2025-09-09 23:39:40 - Newser
Chart based exit strategy for Spyre Therapeutics Inc.Share Buyback & Real-Time Buy Signal Notifications - Newser
Can Spyre Therapeutics Inc. recover in the next quarterPortfolio Gains Summary & Safe Capital Growth Trade Ideas - Newser
What technical models suggest about Spyre Therapeutics Inc.’s comebackLayoff News & Community Consensus Stock Picks - Newser
Published on: 2025-09-09 07:10:47 - Newser
Tools to assess Spyre Therapeutics Inc.’s risk profileJuly 2025 Sentiment & Daily Volume Surge Trade Alerts - Newser
Can Spyre Therapeutics Inc. hit a new high this monthTrade Ideas & High Accuracy Swing Entry Alerts - Newser
How to build a custom watchlist for Spyre Therapeutics Inc.Weekly Market Report & Safe Entry Trade Signal Reports - Newser
Spyre Therapeutics Inc.’s volatility index tracking explainedPortfolio Profit Report & Smart Allocation Stock Tips - Newser
what’s next for spyre therapeutics inc. stock priceMarket Growth Summary & Long-Term Safe Investment Ideas - Newser
Spyre Therapeutics Inc Stock (SYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):